Related Experiment Video
Updated: Jul 29, 2026
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
Published on: March 7, 2011
Neuropeptide receptor status in human tumor cell lines
T Petit1, K K Davidson, R A Lawrence
1Institute for Drug Development, Cancer Therapy Research Center, San Antonio, TX 78245, USA.
Abstract:
Tumor types expressing a neuroendocrine phenotype secrete neuropeptides with paracrine or autocrine growth factor activity. The efficacy of these paracrine or autocrine loops depends on the expression of specific receptors on tumor cells. Once specific receptors are identified, specific neuropeptide antagonists disrupting paracrine and autocrine loops could be potential treatments in neuropeptide-secreting tumors. In the present study, 11 human tumor cell lines representing astrocytoma, lymphoma, and pancreatic, prostate, lung and colon carcinomas were examined for expression of five different neuropeptide receptors (cholecystokinin, neurotensin, vasopressin, tachykinine substance P and cannabinoid) using RT-PCR and radioligand binding. The presence of various neuropeptide receptors in different human cancer cell lines supports development of new antitumor treatments based on disruption of neuropeptide autocrine growth pathways.
Insights
Tumor cells use neuropeptides for growth. Researchers found specific neuropeptide receptors on various cancer cell lines, suggesting new treatments targeting these pathways for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Neuroendocrine tumors secrete neuropeptides that can stimulate tumor growth through paracrine or autocrine signaling pathways.
- The effectiveness of these growth loops relies on the presence of specific neuropeptide receptors on the tumor cells themselves.
Purpose of the Study:
- To investigate the expression of key neuropeptide receptors in a diverse panel of human cancer cell lines.
- To determine the potential for targeting these receptors with novel therapeutic agents.
Main Methods:
- Utilized reverse transcription-polymerase chain reaction (RT-PCR) to detect receptor gene expression.
- Employed radioligand binding assays to confirm receptor presence and functionality.
Main Results:
- Identified the expression of multiple neuropeptide receptors, including cholecystokinin, neurotensin, vasopressin, tachykinin substance P, and cannabinoid receptors, across various cancer cell lines.
- Demonstrated the presence of these receptors in astrocytoma, lymphoma, pancreatic, prostate, lung, and colon carcinoma cell lines.
Conclusions:
- The widespread expression of neuropeptide receptors in different human cancer types provides a strong rationale for developing targeted therapies.
- Disrupting neuropeptide autocrine growth pathways through receptor antagonists represents a promising strategy for novel antitumor treatments.
